Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab versus macular grid laser for macular oedema due to branch retinal vein occlusion
ACTRN12611000302954Phase 3Recruiting
- Sponsor
- Royal Adelaide Hospital
- Start
- Dec 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in branch retinal vein occlusion (BRVO) (2 arms), sponsored by Royal Adelaide Hospital. Primary endpoint: Best corrected visual acuity. Started Dec 2008; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on ACTRN12611000302954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000302954.